Exchange: NASDAQ·Updated 12:46 PM EDT
ZYME logo

ZYME Zymeworks Inc

$28.82
$0.55
(1.95%)
Today
Reported EarningsAug 6
Mkt Cap$2.02B
Vol109,635.00

About ZYME

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
59

Bullish Sentiment

How do you feel about ZYME?

Advertisement|Remove ads.